Patent: 10,980,890
✉ Email this page to a colleague
Summary for Patent: 10,980,890
| Title: | Compounds comprising self-immolative group |
| Abstract: | Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity. |
| Inventor(s): | Yong Zu Kim, Tae Kyo Park, Sung Ho Woo, Sun Young Kim, Jong Un Cho, Doo Hwan Jung, Ji Young Min, Hyang Sook Lee, Yun hee Park, Jeong Hee Ryu, Kyu Man OH, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Jeon Yang |
| Assignee: | Ligachem Biosciences Inc |
| Application Number: | US16/545,869 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,980,890
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 22-Dec-94 | ⤷ Start Trial | 2039-08-20 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 26-Nov-97 | ⤷ Start Trial | 2039-08-20 |
| Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 19-Feb-02 | ⤷ Start Trial | 2039-08-20 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 10-Dec-97 | ⤷ Start Trial | 2039-08-20 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 12-May-98 | ⤷ Start Trial | 2039-08-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
